Analysts Raise Bio-Techne Targets to $68 on Promising FY27 Organic Growth
Stifel Nicolaus raised Bio-Techne’s price target from $60 to $65, implying 13% upside, while Evercore ISI lifted its target from $62 to $68, signaling over 18% potential gains. Analysts cite a Q2 beat but forecast flat mid-year growth and highlight promising FY27 organic growth projections.
1. Stifel and Evercore Raise Price Targets
On February 5, Stifel Nicolaus analyst Daniel Arias reaffirmed a Hold rating and increased the price target on Bio-Techne from $60 to $65, implying 13% upside potential, while Evercore ISI’s Daniel Markowitz maintained an In Line rating and lifted his target from $62 to $68, representing over 18% potential gain.
2. Guidance and Growth Projections
Despite a second-quarter beat, analysts expect flat growth through midyear and a downward revenue adjustment next quarter, but they highlight Bio-Techne’s promising FY27 organic growth projections driven by life sciences instrument and reagent demand.
3. Company Business Overview
Bio-Techne develops and markets instruments, reagents, diagnostic kits, and related services for clinical research, diagnostics, gene therapy and bioprocessing markets, with products spanning antibodies, immunoassay kits and automated protein analysis systems.